Literature DB >> 15618180

Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1.

Alfred Cortés1, Mata Mellombo, Rosella Masciantonio, Vince J Murphy, John C Reeder, Robin F Anders.   

Abstract

Antibody responses against proteins located on the surface or in the apical organelles of merozoites are presumed to be important components of naturally acquired protective immune responses against the malaria parasite Plasmodium falciparum. However, many merozoite antigens are highly polymorphic, and antibodies induced against one particular allelic form might not be effective in controlling growth of parasites expressing alternative forms. The apical membrane antigen 1 (AMA1) is a polymorphic merozoite protein that is a target of naturally acquired invasion-inhibitory antibodies and is a leading asexual-stage vaccine candidate. We characterized the antibody responses against AMA1 in 262 individuals from Papua New Guinea exposed to malaria by using different allelic forms of the full AMA1 ectodomain and some individual subdomains. The majority of individuals had very high levels of antibodies against AMA1. The prevalence and titer of these antibodies increased with age. Although antibodies against conserved regions of the molecule were predominant in the majority of individuals, most plasma samples also contained antibodies directed against polymorphic regions of the antigen. In a few individuals, predominantly from younger age groups, the majority of antibodies against AMA1 were directed against polymorphic epitopes. The D10 allelic form of AMA1 apparently contains most if not all of the epitopes present in the other allelic forms tested, which might argue for its inclusion in future AMA1-based vaccines to be tested. Some important epitopes in AMA1 involved residues located in domain II or III but depended on more than one domain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15618180      PMCID: PMC538974          DOI: 10.1128/IAI.73.1.422-430.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene.

Authors:  S D Polley; D J Conway
Journal:  Genetics       Date:  2001-08       Impact factor: 4.562

2.  Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1.

Authors:  S A Howell; C Withers-Martinez; C H Kocken; A W Thomas; M J Blackman
Journal:  J Biol Chem       Date:  2001-06-08       Impact factor: 5.157

Review 3.  Measuring immune selection.

Authors:  D J Conway; S D Polley
Journal:  Parasitology       Date:  2002       Impact factor: 3.234

4.  Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1.

Authors:  Alfred Cortés; Mata Mellombo; Ivo Mueller; Ariadna Benet; John C Reeder; Robin F Anders
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

5.  A single malaria merozoite serine protease mediates shedding of multiple surface proteins by juxtamembrane cleavage.

Authors:  Steven A Howell; Isabelle Well; Suzanne L Fleck; Catherine Kettleborough; Christine R Collins; Michael J Blackman
Journal:  J Biol Chem       Date:  2003-04-09       Impact factor: 5.157

6.  Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species.

Authors:  T Triglia; J Healer; S R Caruana; A N Hodder; R F Anders; B S Crabb; A F Cowman
Journal:  Mol Microbiol       Date:  2000-11       Impact factor: 3.501

7.  Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli.

Authors:  Sheetij Dutta; P V Lalitha; Lisa A Ware; Arnoldo Barbosa; J Kathleen Moch; Meredith A Vassell; Bader B Fileta; Svetlana Kitov; Nelly Kolodny; D Gray Heppner; J David Haynes; David E Lanar
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

Review 8.  The pathogenic basis of malaria.

Authors:  Louis H Miller; Dror I Baruch; Kevin Marsh; Ogobara K Doumbo
Journal:  Nature       Date:  2002-02-07       Impact factor: 49.962

9.  High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion.

Authors:  Clemens H M Kocken; Chrislaine Withers-Martinez; Martin A Dubbeld; Annemarie van der Wel; Fiona Hackett; Augusto Valderrama; Michael J Blackman; Alan W Thomas
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

10.  Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection.

Authors:  D L Narum; S A Ogun; A W Thomas; A A Holder
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

View more
  41 in total

1.  The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody.

Authors:  A M Coley; K Parisi; R Masciantonio; J Hoeck; J L Casey; V J Murphy; K S Harris; A H Batchelor; R F Anders; M Foley
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Structural basis of antigenic escape of a malaria vaccine candidate.

Authors:  Sheetij Dutta; Seung Yeon Lee; Adrian H Batchelor; David E Lanar
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-16       Impact factor: 11.205

Review 3.  Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design.

Authors:  Rosalynn L Ord; Marilis Rodriguez; Cheryl A Lobo
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya.

Authors:  Faith H A Osier; Gareth D Weedall; Federica Verra; Linda Murungi; Kevin K A Tetteh; Pete Bull; Bart W Faber; Ed Remarque; Alan Thomas; Kevin Marsh; David J Conway
Journal:  Infect Immun       Date:  2010-08-23       Impact factor: 3.441

5.  High-density Peptide Arrays Help to Identify Linear Immunogenic B-cell Epitopes in Individuals Naturally Exposed to Malaria Infection.

Authors:  Thomas Jaenisch; Kirsten Heiss; Nico Fischer; Carolin Geiger; F Ralf Bischoff; Gerhard Moldenhauer; Leszek Rychlewski; Ali Sié; Boubacar Coulibaly; Peter H Seeberger; Lucjan S Wyrwicz; Frank Breitling; Felix F Loeffler
Journal:  Mol Cell Proteomics       Date:  2019-01-10       Impact factor: 5.911

Review 6.  Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.

Authors:  S L Takala; C V Plowe
Journal:  Parasite Immunol       Date:  2009-09       Impact factor: 2.280

7.  Aminoacylation of Plasmodium falciparum tRNA(Asn) and insights in the synthesis of asparagine repeats.

Authors:  Denis Filisetti; Anne Théobald-Dietrich; Nassira Mahmoudi; Joëlle Rudinger-Thirion; Ermanno Candolfi; Magali Frugier
Journal:  J Biol Chem       Date:  2013-11-06       Impact factor: 5.157

8.  In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized.

Authors:  Kazutoyo Miura; Hong Zhou; Olga V Muratova; Andrew C Orcutt; Birgitte Giersing; Louis H Miller; Carole A Long
Journal:  Infect Immun       Date:  2007-10-08       Impact factor: 3.441

9.  Limited global diversity of the Plasmodium vivax merozoite surface protein 4 gene.

Authors:  Chaturong Putaporntip; Somchai Jongwutiwes; Marcelo U Ferreira; Hiroji Kanbara; Rachanee Udomsangpetch; Liwang Cui
Journal:  Infect Genet Evol       Date:  2009-05-04       Impact factor: 3.342

10.  Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity.

Authors:  Kwadwo A Kusi; Bart W Faber; Alan W Thomas; Edmond J Remarque
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.